CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
stereotactic body radiotherapy +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01344356
NCT01344356Phase 4Completed
CompareCT.gov

Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors

Mercy Research·interventional·Posted Apr 29, 2011·Updated Apr 10, 2020

In Brief

A Phase 4 clinical trial evaluating stereotactic body radiotherapy and Stereotactic body radiotherapy for Squamous Cell Carcinoma of the Head and Neck and 7 related conditions. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma, Paraganglioma of Head and Neck, Chordoma of Head and Neck, Chondrosarcoma of Head and Neck, Angiofibroma of Head and Neck
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 29, 2011
Enrollment StartJul 1, 2008
Primary CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 9.8 yearsPosted 15.2 years ago

Interventions

stereotactic body radiotherapyradiation

14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)

Stereotactic body radiotherapyradiation

8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)